die('
Site is under construction
Dear site users
Site is under construction.
The site will be ready in less than 24 hours.
We are sorry for the inconvenience.
www.yektaweb.com
');
Reports of Biochemistry and Molecular Biology
rbmb.net
Basic Sciences
http://rbmb.net
1
admin
2322-3480
2322-3480
10.61882/rbmb
en
jalali
1402
5
1
gregorian
2023
8
1
12
2
online
1
fulltext
en
The Ratio of Cysteine-Rich Angiogenic Inducer 61 to MicroRNA -155 Expression as a Preeclampsia Diagnostic Marker and Predictor of Its Severity
بیوشیمی
Biochemistry
مقالات اصلی
Original Article
<div style="text-align: justify;"><span style="font-size:10pt"><span style="text-justify:kashida"><span style="text-kashida:0%"><span style="line-height:normal"><span style="tab-stops:396.55pt"><span style="font-family:Calibri,sans-serif"><b><i><span lang="EN-GB" style="font-size:12.0pt"><span new="" roman="" style="font-family:" times=""><span style="color:black"><span style="letter-spacing:-.3pt">Background:</span></span></span></span></i></b> <span style="font-size:12.0pt"><span new="" roman="" style="font-family:" times=""><span style="color:black"><span style="letter-spacing:-.3pt">Preeclampsia (PE) is a multisystem pregnancy disorder that increases maternal-perinatal morbidity and mortality significantly. MicroRNA-155 (miR-155) overexpression in the sera of pregnant women has been linked to preeclampsia. Researchers discovered that miR-155 acts during pregnancy by down-regulating and reducing the cysteine-rich angiogenic inducer 61 (CYR61), which causes local ischemia as well as oxidative stress.</span></span></span></span></span></span></span></span></span></span><br>
<br>
<span style="font-size:10pt"><span style="text-justify:kashida"><span style="text-kashida:0%"><span style="line-height:normal"><span style="tab-stops:396.55pt"><span style="font-family:Calibri,sans-serif"><b><i><span lang="EN-GB" style="font-size:12.0pt"><span new="" roman="" style="font-family:" times=""><span style="color:black"><span style="letter-spacing:-.3pt">Methods:</span></span></span></span></i></b><b> </b><span style="font-size:12.0pt"><span new="" roman="" style="font-family:" times=""><span style="color:black"><span style="letter-spacing:-.3pt">The level of miR-155 expression in all serum samples was quantified using real-time polymerase chain reaction (RT-PCR), and serum CYR61 was measured using enzyme-linked immunosorbent assays. Together with the Cyr-61/miR-155 ratio, they were evaluated as biomarkers for PE pathogenesis and severity prediction.</span></span></span></span></span></span></span></span></span></span><br>
<br>
<span style="font-size:10pt"><span style="text-justify:kashida"><span style="text-kashida:0%"><span style="line-height:normal"><span style="tab-stops:396.55pt"><span style="font-family:Calibri,sans-serif"><b><i><span lang="EN-GB" style="font-size:12.0pt"><span new="" roman="" style="font-family:" times=""><span style="color:black"><span style="letter-spacing:-.3pt">Results:</span></span></span></span></i></b><b> </b><span style="font-size:12.0pt"><span new="" roman="" style="font-family:" times=""><span style="color:black"><span style="letter-spacing:-.3pt">MiR-155 expression, serum CYR61 levels, and Cyr-61/miR-155 ratios were all significantly higher in PE patients compared to the control group. Serum CYR61 levels and the Cyr-61/miR-155 ratio differed significantly between mild and severe PE patients.</span></span></span></span></span></span></span></span></span></span><br>
<br>
<span style="font-size:10pt"><span style="text-justify:kashida"><span style="text-kashida:0%"><span style="line-height:normal"><span style="tab-stops:396.55pt"><span style="font-family:Calibri,sans-serif"><b><i><span lang="EN-GB" style="font-size:12.0pt"><span new="" roman="" style="font-family:" times=""><span style="color:black"><span style="letter-spacing:-.3pt">Conclusion:</span></span></span></span></i></b><b> </b><span style="font-size:12.0pt"><span new="" roman="" style="font-family:" times=""><span style="color:black"><span style="letter-spacing:-.3pt">MiR-155 expression, serum CYR61 levels, and Cyr-61/miR-155 may serve as biomarkers for PE pathogenesis and severity prediction.</span></span></span></span></span></span></span></span></span></span></div>
<quillbot-extension-portal></quillbot-extension-portal><quillbot-extension-portal></quillbot-extension-portal><quillbot-extension-portal></quillbot-extension-portal>
Biomarker, Cysteine-Rich Protein 61, MicroRNAs, Pre-Eclampsia.
332
339
http://rbmb.net/browse.php?a_code=A-10-1249-1&slc_lang=en&sid=1
Sarah
Mamdouh Shoeib
100319475328460017978
100319475328460017978
No
Clinical pathology department, Faculty of Medicine, Tanta University, Egypt.
Doaa
Elwy Abdeldaim
100319475328460017979
100319475328460017979
No
Public Health Department, Faculty of Medicine, Tanta University, Tanta.
Shimaa
Samir Mashal
100319475328460017980
100319475328460017980
No
Internal Medicine department, Faculty of Medicine, Tanta University, Egypt.
Rowida
Raafat Ibrahim
owaida.yousef@med.tanta.edu.eg
100319475328460017981
100319475328460017981
Yes
Medical Biochemistry & Molecular Biology Department, Faculty of Medicine, Tanta University, Egypt.
Lamees
Mohamed Dawood
100319475328460017982
100319475328460017982
No
Medical Biochemistry & Molecular Biology Department, Faculty of Medicine, Tanta University, Egypt.
Doaa
Shatat
100319475328460017983
100319475328460017983
No
Gynecology and Obstetrics Department, Faculty of Medicine, Tanta University, Egypt.
Yasmine
Ibrahim El-Masry
100319475328460017984
100319475328460017984
No
Gynecology and Obstetrics Department, Faculty of Medicine, Tanta University, Egypt.
Ahmed
Almeldin
100319475328460017985
100319475328460017985
No
Physiology Department, Faculty of Medicine, Tanta University, Tanta, Egypt.
Radwa
Mahamoud El Sharaby
100319475328460017986
100319475328460017986
No
Clinical pathology department, Faculty of Medicine, Tanta University, Egypt.